Tag: medical

Exclusive: EU to propose delay to medical device law amid supply worries

LONDON, Dec 8 (Reuters) – The EU Well being Commissioner will on Friday suggest extending the deadline for organizations to comply with a new legislation regulating healthcare gadgets, she instructed Reuters on Thursday as medical professionals alert the laws is creating shortages of lifesaving products.

Stella Kyriakides informed Reuters that worries in employing the regulation had been threatening provides of vital gadgets, this kind of as catheters applied for surgeries on newborns with coronary heart conditions.

“Our individuals hope that medical gadgets are harmless and of maximum quality. We have created important progress to set in area new needs for individual security, but troubles however stay,” mentioned Kyriakides in published emailed comments to Reuters.

“This is why, to mitigate any brief-term pitfalls, we will tomorrow announce an extension of the changeover time period to mitigate any danger of shortages.”

Kyriakides will make the proposal at a meeting of EU health and fitness ministers on Friday. She reported in parliament previous month she was contemplating amendments.

A Commission supply said the extension will need an modification to the legislation. Any authorized adjustments would need to have to be authorised by the Council and Parliament.

Kyriakides did not comment on how extensive the extension would be for.

The Healthcare Products Regulation (MDR) came into effect final 12 months and was launched immediately after the 2010 scandal of exploding breast implants created by a French organization that exploited loopholes to provide defective products at profit.

It has extra stringent needs and greater safety benchmarks than the directive it replaced.

Below the new law, all health-related devices, from implants and prosthetics to blood glucose meters and pacemakers sold in the EU need to be re-licensed by May possibly 2024.

A dozen health professionals and producers interviewed by Reuters say supplies of some merchandise are running lower even just before the 2024 deadline.

That is simply because certificates which very last for 5 many years beneath the aged program are expiring and companies are having difficulties to get new types beneath the new legislation. They say the new certification system is sluggish, cumbersome and expensive.

“From the standpoint of medical practitioners, the circumstance is starting to be extra and much more stressing. We are by now observing shortages of some vital healthcare devices, and in a lot of circumstances option products are lacking,” Christiaan Keijzer, president of the Standing Committee of European Doctors (CPME), told Reuters.

He reported that healthcare associations throughout Europe have noted complications with the provide of surgical instruments, in particular in paediatrics, orthopaedics and cardiology, as very well as other gadgets these kinds of as binocular endoscopes, silicone adhesives and blood assortment items.

Facts unveiled by the Fee in a assertion this 7 days ahead of Friday’s conference highlights the issue.

Makers have submitted apps for around 8,000 devices, but a lot less than 2,000 have been permitted.

At that speed, only 7,000 certificates less than the new program will be issued by the May well 2024 deadline, the Commission explained.

The Fee reported there are about 23,000 certificates less than the outdated system which will expire by Could 2024 without having an extension. About 4,300 of those will expire subsequent yr, it explained.

Certificates address a number of units, generating it challenging to estimate the full number of merchandise potentially affected.

Reporting by Maggie Fick editing by Josephine Mason and Elaine Hardcastle

Our Criteria: The Thomson Reuters Trust Ideas.

IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

SAN RAFAEL, Calif. & BARCELONA, December 07, 2022–(Small business WIRE)–IMIDomics, Inc., a biotechnology organization concentrated on the discovery and development of new medications for the cure of patients with immune-mediated inflammatory diseases (IMIDs), announced now the development of an Immunology Advisory Board consisting of a range of scientific and field luminaries with working experience in building and bringing to marketplace new therapies focusing on IMIDs.

“As we proceed to refine our Precision Discovery Engine, transfer ahead with determining and pursuing targets for likely new remedies and forge critical partnership inside of the pharmaceutical and biotechnology room, owning this seasoned, respected and passionate group of advisors will be key to ensuring we’re maximizing the potential of IMIDomics to provide meaningful effects for IMID clients,” claimed Fred Craves, CEO of IMIDomics. “We are honored and thrilled to get the job done intently with just about every of them and tap their unparalleled knowledge.”

Customers of the IMIDomics Immunology Advisory Board consist of:

  • André Veillette, M.D.: Dr. Veillette is a earth-recognized immunologist and medical oncologist who, over the earlier 3 many years, has finished revolutionary get the job done on figuring out and characterizing intracellular molecules and receptors that participate in important roles in typical immune regulation. Dr. Veillete is a member of the COVID-19 Vaccine Activity Force and the Very long COVID Undertaking Force of the Federal government of Canada.

  • Arthur Weiss, M.D., Ph.D.: Dr. Weiss is the Ephraim P. Engleman Distinguished Professor of Rheumatology at the College of California San Francisco the place he has been on school considering the fact that 1985. From 1988 via 2011, he served as Main of Rheumatology at UCSF. Dr. Weiss scientific tests signal transduction in the immune method, concentrating on the roles of tyrosine kinases and phosphatases in regulating lymphocyte activation and how abnormalities in tyrosine phosphorylation pathways lead to immunologically mediated conditions.

  • Dan Littman, M.D., Ph.D.: Dr. Littman, is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the New York University School of Medicine and an investigator of the Howard Hughes Medical lnstitute. Dr. Littman investigates how microbiota and their solutions impact host immune responses, contributing to homeostasis or inflammatory illness. He serves on various educational and business advisory boards and the Pfizer Board of Administrators.

  • Lewis Lanier, Ph.D.: Dr. Lanier is an American Most cancers Culture Professor, and J. Michael Bishop, MD, Distinguished Professor and Chairman of Microbiology and Immunology at the University of California San Francisco, and Director of the Parker Institute for Cancer Immunotherapy. His research group research Pure Killer cells, which recognize and reduce cells that have become transformed or contaminated by viruses. He has served as President of the American Association of Immunologists and is a member of the Countrywide Academy of Sciences.

  • Pablo Engel, M.D., Ph.D.: Dr. Engel is a Professor of Immunology and Head of the Immunology Device in the Office of Biomedical Sciences at the College of Barcelona. His analysis is focused on lymphocyte mobile-surface molecules and their role in the regulation of immune responses. In addition to his research, Pablo has been Secretary Basic of the European Federation of Immunological Societies (EFIS).

ABOUT IMIDOMICS, INC.

IMIDomics, Inc. is a privately held international biotechnology corporation focused on the discovery and growth of new medicines for the therapy of immune-mediated inflammatory health conditions (IMIDs). Using an exclusive industrial license with the Vall d’Hebron Clinic IMID Biobank’s to accessibility anonymized details from extra than 17,000 patients across 150 wellness facilities, IMIDomics specializes in producing exclusive insights into IMID client encounters, situations and underlying disease mechanisms. This facts sorts the foundation of the IMIDomics Precision Discovery™ Engine which leverages point out-of-the-art analytics, machine understanding and bioinformatics abilities to uncover new insights about IMIDs primarily based on precisely outlined patient populations. These insights are enabling new discoveries for remedies, diagnostics and other innovations created to deal with the unmet requires of folks living with these complex and tough ailments.

IMIDomics was established in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Rheumatology Office at the Vall d’Hebron University Clinic, and Dr. Richard M. Myers, President and Scientific Director at the HudsonAlpha Institute for Biotechnology. Current investors in IMIDomics include DNS Funds, Tao Capital, The Pritzker Organization, Evotec and Bristol Myers Squibb. To learn more about IMIDomics, make sure you go to www.imidomics.com.

Perspective source edition on businesswire.com: https://www.businesswire.com/news/house/20221207005088/en/

Contacts

IMIDomics Press Get hold of:
Casey Blickenstaff at Genuine Chemistry
cblickenstaff@realchemistry.com

How CESI Is Helping Develop the Next Generation of Medical Devices | Hartford HealthCare

<< Back How CESI Is Helping Develop the Next Generation of Medical Devices | Hartford HealthCare

December 05, 2022

When Zoll, a global maker of medical devices used to treat patients with serious heart conditions, had an idea for how to build a better defibrillator, they turned to the experts at Hartford HealthCare’s Center for Education, Simulation and Innovation (CESI).&#13
&#13
“They brought in a half-gallon milk carton with markings on the sides to show us what the new defibrillator could look like,’’ said Stephen Donahue, co-founder and director of operations for CESI, describing Zoll’s low-tech prototype.&#13
&#13
The idea was to build a hospital defibrillator that was much simpler to use and provided guidance to inexperienced users, while enabling doctors and nurses familiar with the device to grab it and go if a patient’s heart stops.&#13
&#13
The new defibrillator, now on the market, is just one example of how CESI is fueling life-saving innovation by providing an incubator for the development and testing of medical devices and therapies.&#13
&#13
> Learn much more about Hartford Healthcare’s Middle for Education, Simulation and Innovation (CESI)&#13
&#13
“People appear to us at all stages,’’ stated Steven Shichman, MD, a surgeon and CESI’s govt director. Sometimes they want to kick the tires on an plan, operate it by practitioners. Occasionally, we test a prototype so they can discover out how it performs in the real globe.”&#13
&#13
For example, a company was developing packaging for instruments made use of in working room and intensive care units. To make sure the packaging was straightforward to open up, CESI invited suppliers and nurses to test it in a simulated OR. Organization engineers watched from a remote site so they could identify challenges they may perhaps not have anticipated. HHC end users also provided opinions for how to make the item improved.&#13
&#13
Not too long ago, just one of the world’s most significant health care system organizations accomplished the the vast majority of the Foodstuff and Drug Administration testing of a new robotic surgical platform working with CESI’s state-of-the-artwork labs.&#13
&#13
CESI has been instrumental to HHC’s innovation efforts. This 7 days HHC is celebrating “Innovation Week,” which celebrates how the process is establishing innovative applications, functioning with pioneering partners and advancing new methods to make health care additional accessible, economical, equitable and outstanding for the individuals and communities it serves.&#13
&#13
> Linked: Connecticut Innovations and Hartford Healthcare Announce Partnership&#13
&#13
In its 53,000-square-foot building across the street from Hartford Hospital, CESI homes large-fidelity simulation rooms that appear and feel exactly like genuine operating rooms, ICUs and labor and shipping and delivery rooms. Mannequins can simulate every thing from childbirth to a coronary heart assault. All health care suppliers and product sales reps from health care device corporations can also practice on cadavers and inanimate tissue styles.&#13
&#13
Contracts with some of the world’s major professional medical system companies and the U.S. armed service provide in more than enough profits to assistance CESI’s most important mission to assistance coach all providers in HHC to offer safer and larger excellent treatment to our individuals.&#13
&#13
“We’re not a believe tank,” Shichman stated. “We’re built and staffed to be a resource for the [medical device] market so they can acquire new merchandise.”&#13
&#13
Here’s a enjoyment actuality: CESI’s simulation rooms are so sensible that they have been used as film sets. If you are viewing holiday getaway flicks, examine out “Next Cease, Christmas” on the Hallmark Channel. The clinic scenes ended up filmed at CESI.&#13
&#13
> Want much more health and fitness news? Textual content MoreLife to 31996 to indicator up for textual content alerts

Palo Alto Networks Announces Medical IoT Security to Protect Connected Devices Critical to Patient Care

SANTA CLARA, Calif., Dec. 5, 2022 /PRNewswire/ — As healthcare providers use digital devices such as diagnostic and monitoring systems, ambulance equipment, and surgical robots to improve patient care, the security of those devices is as important as their primary function. Today, Palo Alto Networks (NASDAQ: PANW) announced Medical IoT Security — the most comprehensive Zero Trust security solution for medical devices — enabling healthcare organizations to deploy and manage new connected technologies quickly and securely. Zero Trust is a strategic approach to cybersecurity that secures an organization by eliminating implicit trust by continuously verifying every user and device.

“The proliferation of connected medical devices in the healthcare industry brings a wealth of benefits, but these devices are often not well secured. For example, according to Unit 42, an alarming 75{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} of smart infusion pumps examined on the networks of hospitals and healthcare organizations had known security gaps,” said Anand Oswal, senior vice president of products, network security at Palo Alto Networks. “This makes security devices an attractive target for cyberattackers, potentially exposing patient data and ultimately putting patients at risk.”

While a Zero Trust approach is critical to help protect medical devices against today’s innovative cyberthreats, it can be hard to implement in practice. Through automated device discovery, contextual segmentation, least privilege policy recommendations and one-click enforcement of policies, Palo Alto Networks Medical IoT Security delivers a Zero Trust approach in a seamless, simplified manner. Medical IoT Security also provides best-in-class threat protection through seamless integration with Palo Alto Networks cloud-delivered security services, such as Advanced Threat Prevention and Advanced URL Filtering.

The new Palo Alto Networks Medical IoT Security uses machine learning (ML) to enable healthcare organizations to:

  • Create device rules with automated security responses: Easily create rules that monitor devices for behavioral anomalies and automatically trigger appropriate responses. For example, if a medical device that typically only sends small amounts of data unexpectedly begins to use a lot of bandwidth, the device can be cut off from the internet and security teams can be alerted.
  • Automate Zero Trust policy recommendations and enforcement: Enforce recommended least-privileged access policies for medical devices with one click using Palo Alto Networks Next-Generation Firewalls or supported network enforcement technologies. This eliminates error-prone and time-consuming manual policy creation and scales easily across a set of devices with the same profile.
  • Understand device vulnerabilities and risk posture: Access each medical device’s Software Bill of Materials (SBOM) and map them to Common Vulnerability Exposures (CVEs). This mapping helps identify the software libraries used on medical devices and any associated vulnerabilities. Get immediate insights into the risk posture of each device, including end-of-life status, recall notification, default password alert and unauthorized external website communication.
  • Improve compliance: Easily understand medical device vulnerabilities, patch status and security settings, and then get recommendations to bring devices into compliance with rules and guidelines, such as the Health Insurance Portability Accountability Act (HIPAA), General Data Protection Regulation (GDPR), and similar laws and regulations.
  • Verify network segmentation: Visualize the entire map of connected devices and ensure each device is placed in its designated network segment. Proper network segmentation can ensure a device only communicates with authorized systems.
  • Simplify operations: Two distinct dashboards allow IT and biomedical engineering teams to each see the information critical to their roles. Integration with existing healthcare information management systems, like AIMS and Epic Systems, helps automate workflows.

Healthcare organizations are using Palo Alto Networks products to secure the devices that deliver cutting-edge care to millions of patients all over the world.

“Establishing and maintaining acute situational awareness of the Internet of Medical Things (IoMT) environment is paramount to establishing an effective enterprise cybersecurity program. The ability to accurately detect, identify and respond to cyber threats is critical to ensuring minimal operational impact to clinical operations during a cyber event,” said Tony Lakin, CISO, Moffitt Cancer Center. “Palo Alto Networks IoT capability seamlessly integrates with our continuous monitoring processes and threat-hunting operations. The platform consistently provides my teams with actionable information to allow them to proactively manage the threat surface of our medical device portfolio.”

“With thousands of devices to manage, healthcare environments are extremely complex and require intelligent security solutions capable of doing more. Palo Alto Networks understands this requirement and is leveraging machine learning (ML) for Medical IoT security. Adding intelligence will enable providers to improve operational efficiency, which will enhance patient and practitioner experience and alleviate the burden of an ongoing IT skills shortage,” said Bob Laliberte, principal analyst, ESG.

“Healthcare providers continue to be high-value targets for attackers. This reality, combined with the diversity of medical IoT devices and their inherent vulnerabilities, points to a real need for device security that is purpose-built for healthcare use cases. The ability to defend against threats targeting critical care devices while maintaining operational availability and strengthening the alignment of device governance responsibilities between IT and Biomed engineering teams is quickly becoming a necessity for the protection of patient data and lives,” said Ed Lee, research director, IoT and Intelligent Edge Security, IDC.

More Information

  • Learn more about Medical IoT Security here.
  • Read the Medical IoT Security announcement blog here.
  • Register to attend the Palo Alto Networks Ignite Conference on December 12th – 15th, 2022, here.
  • Follow Palo Alto Networks on Twitter, LinkedIn, Facebook and Instagram.

Availability

Medical IoT Security will be available in January 2023.

About Palo Alto Networks

Palo Alto Networks is the world’s cybersecurity leader. We innovate to outpace cyberthreats, so organizations can embrace technology with confidence. We provide next-gen cybersecurity to thousands of customers globally, across all sectors. Our best-in-class cybersecurity platforms and services are backed by industry-leading threat intelligence and strengthened by state-of-the-art automation. Whether deploying our products to enable the Zero Trust Enterprise, responding to a security incident, or partnering to deliver better security outcomes through a world-class partner ecosystem, we’re committed to helping ensure each day is safer than the one before. It’s what makes us the cybersecurity partner of choice.

At Palo Alto Networks, we’re committed to bringing together the very best people in service of our mission, so we’re also proud to be the cybersecurity workplace of choice, recognized among Newsweek’s Most Loved Workplaces (2021), Comparably Best Companies for Diversity (2021), and HRC Best Places for LGBTQ Equality (2022). For more information, visit www.paloaltonetworks.com.

Palo Alto Networks and the Palo Alto Networks logo are registered trademarks of Palo Alto Networks, Inc. in the United States and in jurisdictions throughout the world. All other trademarks, trade names, or service marks used or mentioned herein belong to their respective owners. Any unreleased services or features (and any services or features not generally available to customers) referenced in this or other press releases or public statements are not currently available (or are not yet generally available to customers) and may not be delivered when expected or at all. Customers who purchase Palo Alto Networks applications should make their purchase decisions based on services and features currently generally available.

SOURCE Palo Alto Networks, Inc.

Biden Signs Medical Marijuana Research Bill

President Joe Biden turns the Healthcare Cannabis Research Bill into legislation, modifying how American experts can do investigate on marijuana.

As predicted by Marijuana Second final week, the White House announced on Friday that President Biden signed the Health-related Cannabis and Cannabidiol Study Enlargement Act, “which establishes a new registration approach for conducting investigation on cannabis and for production cannabis solutions for analysis functions and drug development.”

The bipartisan invoice was launched in July, rapidly passed in the House in the very same thirty day period, and unanimously accredited by the Senate in November.

Rep. Earl Blumenauer (Democrat), who sponsored the bill, unveiled a joint press assertion together with Cannabis Caucus Co-Chairs Barbara Lee (Democrat), Dave Joyce (Republican), and Brian Mast (Republican) stressing the importance of this kind of achievement.

“For decades, the federal government has stood in the way of science and progress—peddling a misguided and discriminatory solution to hashish. These days marks a monumental action in remedying our federal hashish legislation. The Healthcare Cannabis and Cannabidiol Analysis Growth Act will make it much easier to examine the impacts and possible of hashish,” the statement reads.

Moreover, the Reps highlighted how fundamental is health care investigation on cannabis to realize the full medicinal probable of the plant to address a huge array of health care conditions and pledged to do the job on ending the war on medicines through a collection of approaching proposals that will reshape the standing of cannabis at the federal stage.

The legislation substantially eases the life of experts who want to research marijuana for health-related uses, as they experienced to observe strict laws that could delay their investigation.

The new laws removes federal restrictions in order to ease research from researching the plant and speeds up the software course of action to approve cannabis-relevant scientific experiments.

Less than the new law, the federal federal government has to make sure an adequate, uninterrupted provide of marijuana accessible to scientists for studies on clinical cannabis.

Thus, scientists will be equipped to master much more about the plant’s health care qualities and request big quantities of marijuana to use for analysis.

In actuality, the laws now demands that inside of 60 times of getting a researcher’s application, the U.S. Lawyer General has to approve it, request much more facts, or deny it specifying the good reasons. If scientists submit extra facts upon request, the Lawyer Common has 30 times to make a decision.

Universities and exploration establishments will now be able to obtain U.S. Drug Enforcement Administration (DEA) license to mature, manufacture, distribute, dispense and possess cannabis for investigate uses, with advice from the Section of Wellbeing and Human Solutions (HHS) and the U.S. Foodstuff And Drug Administration.

Scientists who want to do marijuana investigation may well update their protocol with no informing the DEA if the quantity and variety of cannabis, the resource, and the storage circumstances of the product would not modify.

The laws also encourages the Fda to produce cannabis-derived medications and addresses the HHS to determine the opportunity healthcare added benefits of cannabis or cannabidiol (or CBD) as a drug.

The Health care Cannabis and Cannabidiol Investigation Growth Act also intervenes in the medical doctor-affected individual marriage by letting medical professionals to talk about the at the moment acknowledged opportunity harms and gains of cannabis cannabinoids, these as CBD, as a therapy or the recognised achievable damages and rewards of cannabis and its compounds.

Even so, the legislation doesn’t allow for scientists to attain marijuana from point out-operate dispensaries and is not going to reschedule marijuana at the federal stage.

In actuality, marijuana will keep on being illegal at the federal stage below Agenda I of the Controlled Substances Act.

Nonetheless, the laws represents a important stage ahead for professional medical exploration on cannabis in the U.S.

Prior to the new law, undertaking investigate on marijuana was incredibly tough in the U.S. as researchers required approval from various organizations to perform scientific studies, which could often consider many years.

On top of that, experts were only allowed to use marijuana developed by the College of Mississippi, although the DEA has a short while ago awarded 6 other marijuana cultivation licenses for investigate to U.S. organizations.

Biden’s signature of The Medical Marijuana and Cannabidiol Investigate Expansion Act follows the executive order in Oct pardoning about 6,500 persons convicted for marijuana possession at the federal degree.

On that situation, he also requested the Secretary of the HHS and the Legal professional Typical to “initiate the approach of examining how marijuana is scheduled beneath federal legislation.”

Despite the fact that the new regulation doesn’t put into practice much more reform at the federal level, it might pave the way for new federal legislation on cannabis, these types of as the Risk-free Banking Act, that may simplicity the federal limitations on the cannabis industry.

Huntington Medical Research Institutes to Host Holiday Open House Commemorating 70th Anniversary

Milestone anniversary celebrates Pasadena-based organization’s huge contribution to transforming medicine and saving millions of lives

PASADENA, Calif., December 02, 2022–(BUSINESS WIRE)–Huntington Medical Research Institutes (HMRI), a leading biomedical research organization in Southern California, is celebrating its 70th anniversary by opening its doors to the public this Saturday, December 3, 2022, from 11 a.m. to 3 p.m. for its Holiday Open House.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221202005288/en/

Huntington Medical Research Institutes to Host Holiday Open House Commemorating 70th Anniversary

HMRI 70th Anniversary Holiday Open House (Graphic: Business Wire)

The event is free to attend (registration requested) and offers:

  • Hands-on science activities for kids

  • Information on HMRI’s summer 2023 education programs for high school and college students

  • Talks with HMRI scientists on their latest discoveries about Alzheimer’s disease, mental illness, heart health, Covid-19 and more

  • Games, music, art and food trucks

“We’re celebrating 70 years of groundbreaking science and we are not done yet,” reflected Julia E. Bradsher, PhD, MBA, president and CEO of HMRI. “We have many more important discoveries in our future as we grow and continue to develop as a leading research institution. We look forward to celebrating many more innovative discoveries in our focus areas of cardiovascular, neurovascular and neuroscience research.”

HMRI began as an outgrowth of two separate institutes: Pasadena Foundation for Medical Research, established in 1952, and the Institute of Medical Research of Huntington Memorial Hospital, founded in 1953. The establishment of a third in 1961, the Neurovascular Research Foundation, formed a triumvirate in Pasadena. After a series of mergers over the course of three decades, in 1982, HMRI as we know it today was born.

For 70 years, the research facilities have generated a multitude of leading-edge innovations that have transformed the way people around the world protect their well-being and improve their health. Some of the noteworthy innovations from HMRI include:

  • Cerebrospinal fluid shunt valve system developed for hydrocephalus, “water on the brain.” The Pudenz valve system is still commonly used today.

  • Retractable seatbelts invented through study of preventing head traumas in car accidents in the 1950s.

  • Early research into prostate cancer cells, resulting in an immortalized cell line which is now widely used to test new prostate cancer drugs.

  • Demonstrating the diagnostic value of magnetic resonance imagining (MRI) in medical practice.

  • Perfecting magnetic resonance spectroscopy for diagnosing brain and heart conditions.

Currently, HMRI’s researchers are exploring new therapies and diagnostic methods that may transform the way we care for our hearts and brains.

HMRI’s mission is to advance scientific discovery through innovative biomedical research to improve health outcomes and inspire the next generation of scientists. “Within 10 years, we aim to become one of the leading biomedical research organizations in the United States,” stated Bradsher.

In addition to scientific discovery, HMRI has a long history of providing research opportunities for postdoctoral scientists and training undergraduate students in laboratory techniques.

“HMRI has welcomed postdoc and student researchers for years now,” explains Nicole Purcell, PhD, scientific director of education programs for HMRI. “We’re teaching research methods to students who are learning in a science lab for the very first time. We want HMRI to be recognized as a destination of choice for the next generation of scientists.”

Members of the media are invited to attend the holiday open house and speak with HMRI’s leading scientists about current research projects and how they see the world of medicine evolving as we approach 2023. Media may register here: https://bit.ly/HMRI70-Media.

Members of the public can register to attend the event here: https://hmri.org/70years/.

About HMRI

Huntington Medical Research Institutes (HMRI) is an independent, nonprofit organization located in Pasadena, California. Since its beginnings in 1952, HMRI research has led to the development of diagnostics, medical devices and therapies that improve the lives of millions of patients worldwide. HMRI conducts life-changing studies of the heart, the brain and the vascular intersection between the two. The institute’s scientists seek solutions to daunting cardiovascular and neurological challenges, like heart disease, Alzheimer’s disease, migraine and mental illness. For more information, visit HMRI.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221202005288/en/

Contacts

Media Contact
Audrey Chittick
mPR on behalf of HMRI
audrey@mpublicrelations.com